MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY
- PMID: 29561981
- DOI: 10.1590/S0004-2803.201800000-07
MEASUREMENT OF CONTROLLED ATTENUATION PARAMETER: A SURROGATE MARKER OF HEPATIC STEATOSIS IN PATIENTS OF NONALCOHOLIC FATTY LIVER DISEASE ON LIFESTYLE MODIFICATION - A PROSPECTIVE FOLLOW-UP STUDY
Abstract
Background: Liver biopsy is a gold standard method for hepatic steatosis assessment. However, liver biopsy is an invasive and painful procedure and can cause severe complications therefore it cannot be frequently used in case of follow-up of patients. Non-invasive assessment of steatosis and fibrosis is of growing relevance in non-alcoholic fatty liver disease (NAFLD). To evaluate hepatic steatosis, transient elastography with controlled attenuation parameter (CAP) measurement is an option now days.
Objective: Aim of this study is to evaluate role of measurement of controlled attenuation parameter, a surrogate marker of hepatic steatosis in patients of nonalcoholic fatty liver disease on lifestyle modification.
Methods: In this study, initially 37 participants were included who were followed up after 6 months with transient elastography, blood biochemical tests and anthropometric measurements. The results were analyzed by Multivariate linear regression analysis and paired samples t-test (Dependent t-test) with 95% confidence interval. Correlation is calculated by Pearson correlation coefficients.
Results: Mean CAP value for assessing hepatic steatosis during 1st consultation (278.57±49.13 dB/m) was significantly improved (P=0.03) after 6 months of lifestyle modification (252.91±62.02 dB/m). Only fasting blood sugar (P=0.008), weight (P=0.000), body mass index (BMI) (P=0.000) showed significant positive correlation with CAP. Only BMI (P=0.034) and weight (P=0.035) were the independent predictor of CAP value in NAFLD patients.
Conclusion: Lifestyle modification improves the hepatic steatosis, and CAP can be used to detect the improvement of hepatic steatosis during follow-up in patients with NAFLD on lifestyle modification. There is no relation between CAP and Fibroscan score in NAFLD patients. Only BMI and weight can predict CAP value independently.
Similar articles
-
Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.J Gastroenterol Hepatol. 2016 Apr;31(4):848-55. doi: 10.1111/jgh.13219. J Gastroenterol Hepatol. 2016. PMID: 26514665
-
Utility of transient elastography (fibroscan) and impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients.Surg Obes Relat Dis. 2018 Jan;14(1):81-91. doi: 10.1016/j.soard.2017.09.005. Epub 2017 Sep 11. Surg Obes Relat Dis. 2018. PMID: 29126863
-
Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.J Gastroenterol Hepatol. 2014;29(7):1470-6. doi: 10.1111/jgh.12557. J Gastroenterol Hepatol. 2014. PMID: 24548002
-
Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis.BMC Gastroenterol. 2019 Apr 8;19(1):51. doi: 10.1186/s12876-019-0961-9. BMC Gastroenterol. 2019. PMID: 30961539 Free PMC article.
-
Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?World J Gastroenterol. 2016 Aug 28;22(32):7236-51. doi: 10.3748/wjg.v22.i32.7236. World J Gastroenterol. 2016. PMID: 27621571 Free PMC article. Review.
Cited by
-
By-products of lithotripsy: Are they related to abdominal fat and wave characteristics?J Taibah Univ Med Sci. 2019 Feb 5;14(2):156-162. doi: 10.1016/j.jtumed.2019.01.003. eCollection 2019 Apr. J Taibah Univ Med Sci. 2019. PMID: 31435406 Free PMC article.
-
Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study.Korean J Intern Med. 2020 Nov;35(6):1346-1353. doi: 10.3904/kjim.2018.309. Epub 2019 Nov 8. Korean J Intern Med. 2020. PMID: 31694366 Free PMC article.
-
Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.Trials. 2024 Jun 11;25(1):374. doi: 10.1186/s13063-024-08208-4. Trials. 2024. PMID: 38858768 Free PMC article.
-
Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease.Cureus. 2021 Jul 15;13(7):e16414. doi: 10.7759/cureus.16414. eCollection 2021 Jul. Cureus. 2021. PMID: 34422459 Free PMC article.
-
Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD).J Clin Exp Hepatol. 2023 Mar-Apr;13(2):273-302. doi: 10.1016/j.jceh.2022.11.014. Epub 2022 Dec 7. J Clin Exp Hepatol. 2023. PMID: 36950481 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous